| pubmed-article:19999133 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19999133 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19999133 | lifeskim:mentions | umls-concept:C0878773 | lld:lifeskim |
| pubmed-article:19999133 | lifeskim:mentions | umls-concept:C0388753 | lld:lifeskim |
| pubmed-article:19999133 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:19999133 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:19999133 | lifeskim:mentions | umls-concept:C0231180 | lld:lifeskim |
| pubmed-article:19999133 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:19999133 | pubmed:dateCreated | 2009-12-11 | lld:pubmed |
| pubmed-article:19999133 | pubmed:abstractText | The efficacy of alpha1-adrenoceptor (alpha1-AR) antagonist and anticholinergic agent combined therapy for patients with benign prostatic hyperplasia (BPH) together with overactive bladder (OAB) has been controversial. The purpose of this study was to evaluate the effect of tolterodine combined with alpha1-AR antagonist for patients with BPH and OAB after insufficient efficacy by monotherapy with alpha1-AR antagonist. The adverse event of this combined therapy was also assessed. | lld:pubmed |
| pubmed-article:19999133 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:19999133 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19999133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19999133 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19999133 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19999133 | pubmed:issn | 0021-5287 | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:UedaTomohiroT | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:OkuyamaAkihik... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:TsujimuraAkir... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:YamamotoKeisu... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:TakahashiToru... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:TakaoTetsuyaT | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:HiraiToshiaki... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:KiuchiHiroshi... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:MiyagawaYasus... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:NakayamaJiroJ | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:FukuharaShini... | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:UchidaKinyaK | lld:pubmed |
| pubmed-article:19999133 | pubmed:author | pubmed-author:KojimaanYasuy... | lld:pubmed |
| pubmed-article:19999133 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19999133 | pubmed:volume | 100 | lld:pubmed |
| pubmed-article:19999133 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19999133 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19999133 | pubmed:pagination | 686-92 | lld:pubmed |
| pubmed-article:19999133 | pubmed:dateRevised | 2011-7-28 | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:meshHeading | pubmed-meshheading:19999133... | lld:pubmed |
| pubmed-article:19999133 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19999133 | pubmed:articleTitle | [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist]. | lld:pubmed |
| pubmed-article:19999133 | pubmed:affiliation | Department of Urology, Osaka University Graduate School of Medicine. | lld:pubmed |
| pubmed-article:19999133 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19999133 | pubmed:publicationType | English Abstract | lld:pubmed |
